Who is sponsoring NCT03514680?

NCT03514680 is sponsored by Dana-Farber Cancer Institute.

What drugs are being tested in NCT03514680?

Interventions in NCT03514680: CIPN Assessment and Management Algorithm.

What condition does NCT03514680 study?

NCT03514680 studies Cancer, Chemotherapy-induced Peripheral Neuropathy.

Is NCT03514680 still recruiting?

NCT03514680 is currently completed. Last updated 16 March 2022.

Last reviewed 2022-03-16 · How we verify

NCT03514680

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinician Decision Support Algorithm for Chemotherapy-Induced Peripheral Neuropathy

Completed NA Last updated 16 March 2022

What this trial tests

NA trial testing CIPN Assessment and Management Algorithm in Cancer in 226 participants. Completed in 23 March 2020.

Timeline

4 June 2018

Primary endpoint
30 December 2019

23 March 2020

Quick facts

Lead sponsor	Dana-Farber Cancer Institute
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	226
Start date	4 June 2018
Primary completion	30 December 2019
Estimated completion	23 March 2020
Sites	1 location across United States

Drugs / interventions tested

CIPN Assessment and Management Algorithm

Conditions studied

Cancer — all drugs for Cancer →
Chemotherapy-induced Peripheral Neuropathy — all drugs for Chemotherapy-induced Peripheral Neuropathy →

Sponsor

Dana-Farber Cancer Institute

Who can join

18 and older, any sex, with Cancer or Chemotherapy-induced Peripheral Neuropathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research study is evaluating how well a decision support tool works to improve clinicians' use of recommended chemotherapy-induced peripheral neuropathy (CIPN) assessment and management strategies in participants receiving chemotherapy.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Exploring the impact of a decision support algorithm to improve clinicians' chemotherapy-induced peripheral neuropathy assessment and management practices: a two-phase, longitudinal study.
Knoerl R, Mazzola E, Hong F, Salehi E, et al · · 2021 · cited 15× · PMID 33676431 · DOI 10.1186/s12885-021-07965-8
The effectiveness of clinical guideline implementation strategies in oncology-a systematic review.
Bora AM, Piechotta V, Kreuzberger N, Monsef I, et al · · 2023 · cited 12× · PMID 37024867 · DOI 10.1186/s12913-023-09189-x
Measurement properties of brief neuropathy screening items in cancer patients receiving taxanes, platinums, or proteasome inhibitors.
Knoerl R, Mazzola E, Mitchell SA, Hong F, et al · · 2021 · cited 12× · PMID 34568984 · DOI 10.1186/s41687-021-00377-z

Verify or expand the search:

Other recruiting trials for Cancer

Currently open trials in the same condition.

NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting

Other Dana-Farber Cancer Institute trials

Trials by the same sponsor.

NCT07519200 — Sexual Health and Rehabilitation for Women With Metastatic Breast Cancer (SHARE-MC): An Educational Intervention · NA · not yet recruiting
NCT07499999 — Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk fo · Phase 2 · not yet recruiting
NCT05825469 — Development and Testing of Nutritional Algorithms (NACHO) · NA · not yet recruiting
NCT07516353 — my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults · NA · not yet recruiting
NCT07513324 — Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03514680 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dana-Farber Cancer Institute
Last refreshed: 16 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03514680.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing